EQT has together with Lars Backsell and Thomas Eldered, founders of Recipharm, announced a takeover bid to the shareholders and holders of convertible bonds of Recipharm AB.
The shareholders of Recipharm are offered SEK 220 in cash per share. The holders of convertible bonds are offered SEK 1,427,010 in cash per SEK 1,000,000 in aggregate principal amount of convertible bonds. The offer thus values Recipharm, based on all outstanding shares and all outstanding convertible bonds, to approximately SEK 23.6 billion. Recipharm is a leading global CDMO (Contract Development and Manufacturing Organisation) that offers manufacturing and development services to companies in the pharmaceutical industry. The class B shares in Recipharm are listed on Nasdaq Stockholm, Mid Cap. The convertible bonds are admitted to trading on the Frankfurt Stock Exchange, Open Market (Freiverkehr). Setterwalls has advised the founders of Recipharm who are participating with EQT in the offer.